TBG Diagnostics
TBG Diagnostics Ltd focuses on the research, development, and manufacturing of molecular diagnostics kits and instruments. The company operates primarily in the InVitro Diagnostics segment, which involves the research of biological drugs and the retail and wholesale distribution of veterinary pharmaceuticals, with a significant presence in Taiwan and China. TBG Diagnostics also offers a range of services through its molecular typing laboratory, which provides HLA-typing services certified by the American Society of Histocompatibility and Immunology. Through these efforts, TBG Diagnostics aims to enhance diagnostic capabilities and contribute to advancements in healthcare.
CellGate
Acquisition in 2008
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.